Myeloproliferative Disorders (JJ Kiladjian, Section Editor)

Current Hematologic Malignancy Reports

, Volume 8, Issue 4, pp 342-350

First online:

Molecular Classification of Myeloproliferative Neoplasms—Pros and Cons

  • Moosa QureshiAffiliated withDepartment of Haematology, University College London Hospitals NHS Foundation Trust, University College London Hospital
  • , Claire HarrisonAffiliated withGuy’s and St Thomas’ NHS Foundation Trust, Guy’s Hospital Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Dameshek first postulated a common myeloproliferative heritage for the myeloproliferative disorders, now termed neoplasms. This prescient observation was validated by the description of a common mutation in exon 14 of JAK2 for patients with essential thrombocythemia, polycythemia vera and primary myelofibrosis. In recent years, our knowledge of the molecular abnormalities underpinning these disorders has expanded significantly. At the same time, we have continued to use a classification based largely upon the first clinical descriptions of these entities, which sometimes proves problematic in differentiating between these conditions and normal reactive processes, myelodysplasia and between the myeloproliferative neoplasm entities themselves. Here, we discuss the pros and cons of a molecular classification and its potential utility in diagnosis, prognosis, and therapeutics.


Myeloproliferative neoplasms Molecular pathology Polycythemia vera Essential thrombocythemia Primary myelofibrosis JAK/STAT Epigenetics Hematologic malignancy